Evidence map›Paper›PMID 37649790›Full record

ArticleTransplantation direct2023

Calcineurin Inhibition in Deceased Organ Donors: A Systematic Review and Meta-analysis of Preclinical Studies.

Frédérick D'Aragon, William Rousseau, Ruth Breau, Daniel Aminaei, Carole Ichai, Gordon J Boyd, Karen E A Burns, Héloïse Cardinal, François-Martin Carrier, Michaël Chassé and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 13 institutions in 2 countries.

Frédérick D'AragonDepartment of Anesthesiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
William RousseauFaculty of Medicine and Health Sciences, Université de Sherbrooke, QC, Canada.
Ruth BreauDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Daniel AminaeiDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Carole IchaiIntensive Care Unit, University Hospital of Nice, Nice, France.
Gordon J BoydDivision of Neurology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Karen E A BurnsDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Héloïse CardinalDepartment of Nephrology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
François-Martin CarrierDepartment of Anesthesiology, Université de Montréal, Montreal, QC, Canada.
Michaël ChasséDepartment of Critical Care, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Prosanto ChaudhuryDepartment of Surgery and Oncology, McGill University, Montreal, QC, Canada.
Sonny DhananiDivision of Critical Care, Department of Pediatrics, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada.
Shane W EnglishOttawa Hospital Research Institute, Ottawa, ON, Canada.
Anne Julie FrenetteFaculty of Pharmacy, Université de Montreal, Montreal, QC, Canada.
Steven HannaFaculty of Medicine and Health Sciences, Université de Sherbrooke, QC, Canada.
Gregory KnollOttawa Hospital Research Institute, Ottawa, ON, Canada.
François LauzierDepartment of Medicine, Université Laval, Quebec City, QC, Canada.
Simon OczkowskiDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Bram RochwergDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Khaled ShamseddinDivision of Nephrology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Marat SlessarevDivision of Critical Care, Department of Medicine, Western University, London, ON, Canada.
Darin TreleavenDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Alexis F TurgeonPopulation Health and Optimal Health Practice Research Unit, CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada.
Matthew J WeissPopulation Health and Optimal Health Practice Research Unit, CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada.
Markus SelznerDepartment of General Surgery, University of Toronto and Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Maureen O MeadeDepartment of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada.
McMaster University · CAUniversité de Sherbrooke · CAImpact · CAOttawa Hospital Research InstituteQueen's University · CAThe Quebec Population Health Research Network · CAUniversité de Montréal · CACentre Hospitalier Universitaire de Nice · FRMcGill University · CAOttawa Hospital · CAToronto General Hospital · CAUniversité Laval · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preconditioning deceased organ donors with calcineurin inhibitors (CNIs) may reduce ischemia-reperfusion injury to improve transplant outcomes. Methods: We searched MEDLINE, EMBASE, Cochrane Library, and conference proceedings for animal models of organ donation and transplantation, comparing donor treatment with CNIs with either placebo or no intervention, and evaluating outcomes for organ transplantation. Reviewers independently screened and selected studies, abstracted data, and assessed the risk of bias and clinical relevance of included studies. Where possible, we pooled results using meta-analysis; otherwise, we summarized findings descriptively. Results: Eighteen studies used various animals and a range of CNI agents and doses and evaluated their effects on a variety of transplant outcomes. The risk of bias and clinical applicability were poorly reported. Pooled analyses suggested benefit of CNI treatment on early graft function in renal transplants (3 studies; serum creatinine: ratio of means [RoM] 0.54; 95% confidence interval [CI], 0.34-0.86) but not for liver transplants (2 studies; serum alanine transaminase: RoM 0.61; 95% CI, 0.30-1.26; and serum aspartate aminotransferase: RoM 0.58; 95% CI, 0.26-1.31). We found no reduction in graft loss at 7 d (2 studies; risk ratio 0.54; 95% CI, 0.08-3.42). CNI treatment was associated with reduced transplant recipient levels of interleukin-6 (4 studies; RoM 0.36; 95% CI, 0.19-0.70), tumor necrosis factor-alpha (5 studies; RoM 0.36; 95% CI, 0.12-1.03), and cellular apoptosis (4 studies; RoM 0.30; 95% CI, 0.19-0.47). Conclusions: Although this compendium of animal experiments suggests that donor preconditioning with CNIs may improve early kidney graft function, the limited ability to reproduce a true clinical environment in animal experiments and to assess for risk of bias in these experiments is a serious weakness that precludes current clinical application.

Identifiers

PMID37649790
PMCPMC10465100
OpenAlexW4386253129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.